Biogen Exercises Option With Ionis to Develop & Commercialize Investigational ASO for SMA

Biogen Inc. and Ionis Pharmaceuticals, Inc. recently announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306…..

Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda & Pepinemab in Patients With Advanced, Recurrent, or Metastatic Head & Neck Squamous Cell Carcinoma Passes Planned Interim Safety Analysis

The Phase 2 segment of the study is now expected to begin enrollment and is expected to accelerate patient accrual…..

Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones

Assembly Biosciences, Inc. recently outlined anticipated progress and milestones for its development pipeline in 2022…..

Inotiv, Inc. & Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics & Biomarkers

Inotiv, Inc. and Synexa Life Sciences recently announced they intend to form a collaboration that will accelerate Inotiv’s development of biomarkers essential to the understanding of safety and efficacy of novel biotherapeutics, enhancing the….

Allarity Therapeutics & Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib & Stenoparib

Allarity Therapeutics, Inc. and Oncoheroes Biosciences, Inc. recently announced they have entered into licensing agreements under which Oncoheroes will acquire exclusive, global development rights to Allarity’s therapeutic candidates….

Cocrystal Pharma’s COVID-19 Oral & Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

Cocrystal Pharma, Inc. recently announced in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant…..

Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics

Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

Heat Biologics, Inc. recently announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM (obiltoxaximab) Injection,….

TFF Pharmaceuticals Announces Final Data From Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

TFF Pharmaceuticals, Inc. recently announced the full readout of safety and pharmacokinetic (PK) data from its Phase 1b study (NCT #04576325) of Inhaled Voriconazole Powder (TFF VORI) in asthma patients….

PharmaTher Enters Process Development Agreement Eith LTS for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. and LTS LOHMANN Therapie-Systeme AG recently announced they have entered into a process development agreement for the clinical trial scale up of PharmaTher’s proprietary….

Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline

Chord Therapeutics recently announced it is being acquired by Merck; the strategic acquisition enables Merck to expand its neurology pipeline to develop Chord’s lead drug….

Kenox Pharmaceuticals Announces Successful Completion of a Pre-IND Meeting With US-FDA for Novel Inhaled Drug-Device Combination Product 

Kenox Pharmaceuticals Inc. has submitted Type B Pre-Investigational New Drug (IND) meeting request with the US FDA for its lead program KNX018, a novel inhaled drug-device combination product as an….

Novartis Strengthens Immunotherapy Pipeline With Option, Collaboration & License Agreement With BeiGene

Novartis recently announced the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company’s research and development activities in immuno-oncology….

Dyadic Announces Research, License & Collaboration Agreement With Janssen for the Manufacture of Therapeutic Protein Candidates Using its C1 Platform

Dyadic International, Inc. recently announced it has entered into a Research, License and Collaboration Agreement  with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson…..

Metrion Biosciences & Bioqube Ventures Collaborate on Venture Creation Project to Identify Novel Ion Channel Inhibitors for Autoimmune Diseases

Metrion Biosciences Limited and Bioqube Ventures recently announced they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting….

Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover & Develop Novel Therapeutic Antibodies Against GPCR Targets

Sosei Group Corporation and Twist Bioscience Corporation recently announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by….

InveniAI LLC and Kyowa Kirin Co., Ltd. expanded their long-standing relationship with a new, multiple drug discovery agreement. The collaboration will provide Kyowa Kirin with access to InveniAI’s AI Innovation Lab and….

Alcami Announces the Acquisition of Masy BioServices.

Alcami Corporation recently announced it has completed the acquisition of Masy Systems Inc. (Masy or Masy BioServices), a preferred provider of cGMP Biostorage and pharma support services…..

Aragen Acquires Intox Pvt. Ltd

Aragen Life Sciences recently announced it has signed a definitive agreement to acquire Pune-based Intox Pvt. Ltd. This acquisition will expand Aragen’s end-to-end….

Apellis & Sobi Announce EU Approval of Aspaveli (pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB recently announced the European Commission (EC) has approved Aspaveli (pegcetacoplan), the first and only targeted C3 therapy, for the treatment of….